Pricing Sign in

PYXS

Pyxis Oncology, Incdistress 4/10 · elevated risk

$2.62+3%today-51% from 52w high

pyxisoncology.com56 employeesFounded 2018Boston, MABiotechnology

Oncology 1

Lead: HNSCC

Revenue

$14M

Liquidity

$41M

Runway

0.6 yrs

Shares 1y

+2%

Price & events

+52.9% over 6M

CatalystRating changeDilutionFinancingdashed = today

+3.4%

1D

+17.3%

1W

+24.5%

1M

+52.9%

3M

+60.4%

6M

+121.6%

1Y

-33.6%

2Y

—

5Y

-80.2%

All

Overview

Market Cap: $165.67M
Volume: 204.42K
52 Week Range: $1.04 – $5.34
Total Shares: 63.36M
Float Shares: 29.41M
Short %: 4.89%
% Held by Insiders: 13.60%
% Held by Institutions: 42.44%
RVOL: 0.17x
Beta: 1.31

Pipeline stages · 1 programs

PYX-201, pembrolizumab

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-04-25

Pipeline · 3 trials · 2 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2027-04-25 Estimated 50% readout ~2027-05-25	Phase 1	PYX-201fast track	Solid Tumor, Advanced Solid Tumor	—	recruiting
2027-12-06 Estimated 50% readout ~2028-01-20	Phase 1/2	PYX-201, pembrolizumabfast track	Advanced Solid Tumors	—	recruiting
2026-05	Phase 1	PYX-106fast track	Solid Tumor	47	active not recruiting

Catalyst news & presentations · 14

fourth quarter of 2026Guided 70%readoutPhase 1/2micvotabart pelidotin · Updated Phase 1/2 combination data with pembrolizumab in 1L R/M HNSCCSEC 8-K
2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
mid-year 2026readoutPhase 1micvotabart pelidotin · Updated data from Phase 1 monotherapy studySEC 8-K
first half of 2026readoutPhase 1PYX-201 · Preliminary data from dose expansion cohorts expectedSEC 8-K
mid-2026readoutPhase 1MICVO · Updated Phase 1 monotherapy data in 2L+ R/M HNSCCSEC 8-K
2025-12-31fda agreementmicvotabart pelidotin · FDA alignment on pivotal monotherapy trial designSEC 8-K
second half of 2025readoutPhase 1micvotabart pelidotin · Preliminary data from monotherapy expansion cohort in 2L/3L patientsSEC 8-K
second half of 2025readoutPhase 1PYX-201 · Preliminary data from dose expansion cohorts expectedSEC 8-K
second half of 2025readoutPhase 1/2micvotabart pelidotin (MICVO) in combination with pembrolizumab · Preliminary data from Phase 1/2 combination studySEC 8-K
mid-2025readoutPhase 1micvotabart pelidotin · Combo dose selection for MICVO + KEYTRUDASEC 8-K
Q1 2025trial initiationsecondaryPhase 1/2PYX-201 · Phase 1/2 combination trial PYX-201-102 with pembrolizumabSEC 8-K
2025-03-18partnershipmicvotabart pelidotin · Clinical Trial Collaboration Agreement with Merck for combination studySEC 8-K
2024-12-19trial discontinuedPYX-106 · Deprioritized and suspended further clinical investment in Phase 1 monotherapy trialSEC 8-K
2024-11-20partnershipPYX-201 · Clinical trial collaboration with Merck to evaluate PYX-201 with Keytruda; funded supply of Keytruda.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 63,355,482 · 0 offerings/1y · 1 PIPEs

2026-07-028-Kprivate_placement
2025-12-09EFFECTshelf_effective
2025-11-26S-3shelf_registration
2024-11-12SC 13G/Astrategic_stake
2024-11-06SC 13G/Astrategic_stake

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Wall St ratings

strong buy · target $7 (+158% upside) · 8 analysts

2026-07-02Leerink PartnersOutperform
2026-05-05WedbushOutperform
2026-03-24StifelBuy
2026-03-24HC Wainwright & Co.Buy
2025-12-19RBC CapitalOutperform
2025-12-19HC Wainwright & Co.Buy

Competitors — HNSCC

BEIGFBeOne Medicines Ltd.$31.7B · D1
BCAXBicara Therapeutics Inc.$1.8B · D2
INBXInhibrx Biosciences, Inc.$1.2B · D3
KURAKura Oncology, Inc.$917M · D5
RXRXRECURSION PHARMACEUTICALS, INC.$502M · D4
CGENCOMPUGEN LTD$227M · D1
CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
BOLDBoundless Bio, Inc.$57M · D2
PDSBPDS Biotechnology Corp$40M · D7

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.